Esperion Therapeutics Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Esperion Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View analyst ratings for Esperion Therapeutics or view top-rated stocks.

8 equities research analysts have issued twelve-month price targets for Esperion Therapeutics' shares. Their ESPR stock forecasts range from $5.00 to $90.00. On average, they expect Esperion Therapeutics' stock price to reach $21.11 in the next year. This suggests a possible upside of 226.8% from the stock's current price.
View analysts' price targets for Esperion Therapeutics or view top-rated stocks among Wall Street analysts.

Esperion Therapeutics' stock was trading at $5.00 at the beginning of the year. Since then, ESPR shares have increased by 29.2% and is now trading at $6.46.
View the best growth stocks for 2022 here.

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Esperion Therapeutics.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) posted its quarterly earnings results on Tuesday, May, 3rd. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.03. The biopharmaceutical company earned $18.84 million during the quarter, compared to the consensus estimate of $15.41 million. Esperion Therapeutics's revenue was up 136.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($3.50) EPS.
View Esperion Therapeutics' earnings history.

20 employees have rated Esperion Therapeutics CEO Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among Esperion Therapeutics' employees.

Some companies that are related to Esperion Therapeutics include Lyell Immunopharma (LYEL), Amphastar Pharmaceuticals (AMPH), Xencor (XNCR), Aurinia Pharmaceuticals (AUPH), Travere Therapeutics (TVTX), Dynavax Technologies (DVAX), Supernus Pharmaceuticals (SUPN), Ligand Pharmaceuticals (LGND), Cryoport (CYRX), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), Sierra Oncology (SRRA), Day One Biopharmaceuticals (DAWN), BridgeBio Pharma (BBIO) and Axsome Therapeutics (AXSM).
View all of ESPR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Esperion Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (12.93%), Deep Track Capital LP (9.52%), Vanguard Group Inc. (7.13%), Bellevue Group AG (6.82%), Paradigm Biocapital Advisors LP (1.84%) and Rhenman & Partners Asset Management AB (1.56%). Company insiders that own Esperion Therapeutics stock include Eric Warren, Sheldon L Koenig, Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends for Esperion Therapeutics.

ESPR stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Walleye Trading LLC, State Street Corp, Monaco Asset Management SAM, PDT Partners LLC, UBS Group AG, Group One Trading L.P., and Bank of America Corp DE. Company insiders that have sold Esperion Therapeutics company stock in the last two years include Eric Warren, and Sheldon L Koenig.
View insider buying and selling activity for Esperion Therapeutics or view top insider-selling stocks.

ESPR stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Vanguard Group Inc., Renaissance Technologies LLC, Deep Track Capital LP, Paradigm Biocapital Advisors LP, Northern Trust Corp, Bank of New York Mellon Corp, and Goldman Sachs Group Inc..
View insider buying and selling activity for Esperion Therapeutics or or view top insider-buying stocks.

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ESPR stock can currently be purchased for approximately $6.46.

Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $407.03 million and generates $78.45 million in revenue each year. The biopharmaceutical company earns $-269.11 million in net income (profit) each year or ($6.99) on an earnings per share basis.

Esperion Therapeutics employs 218 workers across the globe.

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for Esperion Therapeutics is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at [email protected].